DB18565ExperimentalProtein Based Therapies
Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.
- Also known as
- Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1 and the cyclic RGD-4C peptide (ACDCRGDCFCG)
Resolves to
Compound
Which companies are running trials of Ergidina, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account